

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul S. Keim et al.

Serial No.: tba

Filed: December 21, 2004

For: *A HIGH RESOLUTION TYPING SYSTEM FOR
PATHOGENIC BORRELIA*

Art Unit: tba

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Dear Sir:

Applicant hereby brings to the attention of the Examiner the documents noted on the accompanying Form PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action.

It is respectfully requested that the information cited herein be expressly considered during the prosecution of this application and made of record on any patent to issue therefrom. Inclusion of a reference on the enclosed 1449 is not to be construed as indicating the reference is prior art. Provision of this Information Disclosure Statement is not to be taken as evidence that a search has been conducted.

The Commissioner is hereby authorized to charge any cost that may be due to Deposit Account No. 17-0055.

Respectfully submitted,
QUARLES & BRADY STREICH LANG, LLPDecember 21, 2004By: Barbara J. Luther
Barbara J. Luther, 33,954

Attorney Docket No. 112624.00082

Address all correspondence to:Barbara J. Luther
One Renaissance Square
Two North Central Avenue
Phoenix, AZ 85004
Telephone: 602-230-5502
Facsimile: 602-229-5690
Email: bluther@quarles.com

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Paul S. Keim
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	112624.00082

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	E	WO98/58943 A1	12-30-98	Fraser et al.		

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Paul S. Keim
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	112624.00082

Sheet	2	of	5
-------	---	----	---

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	F	ANDERSON, J. F. 1991. Epizootology of Lyme borreliosis. Scand. J. Infect. Dis. Suppl. 77:23-34.	
	G	BALMELLI, T., 1995. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. Res. Microbiol. 146:329-340.	
	H	BARBOUR, A. G., 1993. The biological and social phenomenon of Lyme disease. Science 260:1610-1616.	
	I	BELFAIZA, D., 1993 Genomic fingerprinting of Borrelia burgdorferi sensu lato by pulsed-field gel electrophoresis. J. Clin. Microbiol. 31:2873-2877	
	J	BURGDORFER, W., 1991. Relationship of Borrelia burgdorferi to its arthropod vectors. Scand. J. Infect. Dis. Suppl. 77:35-40.	
	K	BUSCH, U., 1996. Three species of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto, B. afzelii, and B. garinii) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis and PCR. J. Clin. Microbiol. 34:1072-1078.	
	L	CASJENS S, 2000. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol Microbiol. 35:490-516.	
	M	CASJENS S., 1995 Linear chromosomes of Lyme disease agent spirochetes: genetic diversity and conservation of gene order. J. Bacteriol. 177:2769-2780	
	N	CENTERS FOR DISEASE CONTROL AND PREVENTION. Lyme disease-United States, 1997. Morbid. Mortal. Weekly Rep. 46:531-535.	
	O	CENTERS FOR DISEASE CONTROL AND PREVENTION. 1999. Availability of Lyme disease vaccine. Morbid. Mortal. Weekly Rep. 48:35-36, 41.10	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

5

Application Number

Filing Date

First Named Inventor

Paul S. Keim

Art Unit

tba

Examiner Name

tba

Attorney Docket Number

112624.00082

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P	DYKHUIZEN D.E. et al., 2001. The implications of a low rate of horizontal transfer in <i>Borrelia</i> . Trends Microbiol. 9:344-50.	
	Q	DYKHUIZEN D. E. et al., 1993. <i>Borrelia burgdorferi</i> is clonal: implications for taxonomy and vaccine development. Proc. Natl. Acad. Sci. USA 90: 10163-10167.	
	R	EGGERS C.H. et al., 2001. Transduction by phiBB-1, a bacteriophage of <i>Borrelia burgdorferi</i> . J Bacteriol. 183:4771-8	
	S	FARLOW J, et al. Francisella tularensis Strain Typing Using Multiple-Locus, Variable-Number Tandem Repeat Analysis. J Clin Microbiol. 2001 39:3186-92.	
	T	FORTEZ, M., D. et al., 1997 Phylogenetic analysis of <i>Borrelia burgdorferi</i> sensu stricto by arbitrarily primed PCR and pulsed-field gel electrophoresis Int. J. System. Bacteriol. 47:11-18	
	U	FRASER, C. M., et al., 1997. Genomic sequence of a Lyme disease spirochaete, <i>Borrelia burgdorferi</i> . Nature 390:580-586.	
	V	FUKUNAGA, M., et al., 1996. <i>Borrelia tanukii</i> sp. nov. and <i>Borrelia turdae</i> sp. nov. found from ixodid ticks in Japan: rapid species identification by 16S rRNA gene-targeted PCR analysis. Microbiol. Immunol. 40:877-881.	
	W	GERN, L., A. et al., 1998. Euro-pean reservoir hosts of <i>Borrelia burgdorferi</i> sensu lato. Zentbl. Bakteriol. 287:196-204.	
	X	HUBULEK, Z., et al., 1997. Distribution of <i>Borrelia burgdorferi</i> sensu lato genomic groups in Europe, a review. Eur. J. Epidemiol. 13:951- 957.	
	Y	KAWABATA, H., et al., 1993. Genomic analysis of <i>Borrelia japonica</i> sp. nov. isolated from Ixodes ovatus in Japan. Microbiol. Immunol. 37:841-848.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Paul S. Keim
		Art Unit	tba
		Examiner Name	tba
Sheet 4	of 5	Attorney Docket Number	112624.00082

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	Z	KEIM P. et al., 2000. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within <i>Bacillus anthracis</i> . J Bacteriol May; 182:2928-36.	
	AA	MARCONI, R. T., et al., 1995. Identification of novel insertion elements, restriction fragment length polymorphism patterns, and discontinuous 23S rRNA in Lyme disease spirochetes: phylogenetic analyses of rRNA genes and their intergenic spacers in	
	AB	MARTI Ras., et al., 1997 <i>Borrelia burgdorferi sensu stricto</i> , a bacterial species "made in the USA"? Int. J. System. Bacteriol. 47: 1112-1117	
	AC	MURRAY, P.R., et al., 1999. Manual of Clinical Microbiology. 7th edition. ASM Press, Washington D.C.	
	AD	NADELMAN, R. B., et al., 1998. Lyme borreliosis. Lancet 352:557-565.	
	AE	NICHOLLS, T. H., et al., 1996. Lyme disease spirochetes in ticks collected from birds in mid-western United States. J. Med. Entomol. 33:379-384.	
	AF	OHLENBUSCH, A., et al., 1996. Etiology of the acrodermatitis chronica atrophicans lesion in Lyme disease. J. Infect. Dis. 174:421-423.	
	AG	PETER, O., et al., 1997. Association of distinct species of <i>Borrelia burgdorferi sensu lato</i> with neuroborreliosis in Switzerland. Clin. Microbiol. Infect. 3:423-411.	
	AH	PICKEN, R. N., et al., 1998. Identification of three species of <i>Borrelia burgdorferi sensu lato</i> (<i>B. burgdorferi sensu stricto</i> , <i>B. garinii</i> , and <i>B. afzelii</i>) among isolates from <i>acrodermatitis chronica atrophicans</i> lesions. J. Invest. Dermatol. 110:211-214	
	AI	POSTIC D., et al., 1999 Common ancestry of <i>Borrelia burgdorferi sensu lato</i> strains from North America and Europe. J. Clin. Microbiol. 37:3010-3012	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	
		Filing Date	
		First Named Inventor	Paul S. Keim
		Art Unit	tba
		Examiner Name	tba
Sheet 5	of 5	Attorney Docket Number	112624.00082

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AJ	POSTIC, D., et al., 1998. Expanded Diversity among California Borrelia isolates and description of Borrelia bissetii sp. nov. (formerly Borrelia group DN127). J. Clin. Microbiol. 36:3497-3504	
	AK	SCHMID, G. P. 1985. The global distribution of Lyme disease. Rev. Infect. Dis. 7:41-50.	
	AL	WANG, G., et al., 1999. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical Implications. Clin. Micr. Rev. 12:633-653.	
	AM	WEIR, B.S. 1990. Genetic Data Analysis. Sinauer Associates, Inc. Sunderland, MA. USA.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.